| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
145,981,000 |
| Market
Cap: |
322.62(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.13 - $2.88 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Regulus Therapeutics is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat diseases. Co.'s key product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. Co. has multiple programs in various stages of preclinical development including RGLS5579 as a clinical candidate in its glioblastoma multiforme program, its preclinical programs targeting the Hepatitis B virus and Non-Alcoholic Steatohepatitis program.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
25,516 |
25,516 |
25,516 |
| Total Sell Value |
$0 |
$30,379 |
$30,379 |
$30,379 |
| Total People Sold |
0 |
3 |
3 |
3 |
| Total Sell Transactions |
0 |
3 |
3 |
3 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hagan Joseph P |
Chief Operating Officer |
• – – |
2016-03-03 |
4 |
B |
$7.19 |
$71,900 |
D/D |
10,000 |
10,000 |
2.74 |
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2016-02-23 |
4 |
S |
$7.18 |
$7,180,000 |
D/D |
(1,000,000) |
4,896,716 |
|
- |
|
| Foletta Mark G |
Director |
– • – |
2015-08-13 |
4 |
B |
$7.64 |
$76,405 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2015-08-07 |
4 |
OE |
$0.38 |
$78,801 |
D/D |
50,677 |
200,677 |
|
- |
|
| Rastetter William H |
Director |
– • – |
2015-07-21 |
4 |
B |
$10.19 |
$624,199 |
I/I |
61,235 |
100,000 |
2.1 |
- |
|
| Rastetter William H |
Director |
– • – |
2015-07-20 |
4 |
B |
$10.13 |
$392,779 |
I/I |
38,765 |
38,765 |
2.1 |
- |
|
| Isis Pharmaceuticals Inc |
10% Owner |
– – • |
2015-07-17 |
4 |
S |
$10.21 |
$1,133,754 |
D/D |
(111,000) |
5,173,172 |
|
- |
|
| Isis Pharmaceuticals Inc |
10% Owner |
– – • |
2015-07-16 |
4 |
S |
$10.79 |
$1,801,362 |
D/D |
(167,000) |
5,284,172 |
|
- |
|
| Isis Pharmaceuticals Inc |
10% Owner |
– – • |
2015-07-15 |
4 |
S |
$10.76 |
$700,961 |
D/D |
(65,133) |
5,451,172 |
|
- |
|
| Isis Pharmaceuticals Inc |
10% Owner |
– – • |
2015-06-30 |
4 |
S |
$10.79 |
$143,010 |
D/D |
(13,248) |
5,516,305 |
|
- |
|
| Isis Pharmaceuticals Inc |
10% Owner |
– – • |
2015-06-23 |
4 |
GA |
$0.00 |
$0 |
D/D |
13,248 |
5,529,553 |
|
- |
|
| Xanthopoulos Kleanthis G |
President and CEO |
• • – |
2015-04-21 |
4 |
AS |
$17.73 |
$1,063,980 |
D/D |
(60,000) |
3,705 |
|
- |
|
| Xanthopoulos Kleanthis G |
President and CEO |
• • – |
2015-04-21 |
4 |
OE |
$0.38 |
$22,800 |
D/D |
60,000 |
63,705 |
|
- |
|
| Xanthopoulos Kleanthis G |
President and CEO |
• • – |
2015-04-20 |
4 |
AS |
$16.85 |
$1,113,514 |
D/D |
(66,071) |
3,705 |
|
- |
|
| Xanthopoulos Kleanthis G |
President and CEO |
• • – |
2015-04-20 |
4 |
OE |
$0.38 |
$25,107 |
D/D |
66,071 |
69,776 |
|
- |
|
| Xanthopoulos Kleanthis G |
President and CEO |
• • – |
2015-04-17 |
4 |
AS |
$16.94 |
$1,252,002 |
D/D |
(73,929) |
3,705 |
|
- |
|
| Xanthopoulos Kleanthis G |
President and CEO |
• • – |
2015-04-17 |
4 |
OE |
$0.38 |
$28,093 |
D/D |
73,929 |
77,634 |
|
- |
|
| Carter Bruce L A |
Director |
– • – |
2015-04-13 |
4 |
S |
$17.66 |
$353,164 |
D/D |
(20,000) |
0 |
|
- |
|
| Carter Bruce L A |
Director |
– • – |
2015-04-13 |
4 |
OE |
$4.78 |
$95,600 |
D/D |
20,000 |
20,000 |
|
- |
|
| Xanthopoulos Kleanthis G |
President and CEO |
• • – |
2015-03-05 |
4 |
AS |
$20.06 |
$1,808,063 |
D/D |
(89,230) |
2,466 |
|
- |
|
| Xanthopoulos Kleanthis G |
President and CEO |
• • – |
2015-03-05 |
4 |
OE |
$0.38 |
$33,907 |
D/D |
89,230 |
91,696 |
|
- |
|
| Xanthopoulos Kleanthis G |
President and CEO |
• • – |
2015-02-27 |
4 |
AS |
$19.50 |
$1,365 |
D/D |
(70) |
2,466 |
|
- |
|
| Xanthopoulos Kleanthis G |
President and CEO |
• • – |
2015-02-27 |
4 |
OE |
$0.38 |
$27 |
D/D |
70 |
2,536 |
|
- |
|
| Xanthopoulos Kleanthis G |
President and CEO |
• • – |
2015-02-02 |
4 |
AS |
$19.77 |
$47,440 |
D/D |
(2,400) |
2,466 |
|
- |
|
| Xanthopoulos Kleanthis G |
President and CEO |
• • – |
2015-02-02 |
4 |
OE |
$0.38 |
$912 |
D/D |
2,400 |
4,866 |
|
- |
|
341 Records found
|
|
Page 6 of 14 |
|
|
0.04 (1.78%) 
